2024-515352-20-00招募中2 期
IDIOME study: A single-arm phase II multicenter study of IDH1 (AG-120) inhibitor in patients with IDH1 mutated Myelodysplastic Syndrome
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 48
- 试验地点
- 25
- 主要终点
- Overall hematological response at 3 and 6 months (including CR, PR, stable disease with HI according to IWG 2006) for cohort A and B; SAFETY FOR COHORT C
研究概览
简要总结
Cohorts A and B: To determine the response rate (CR+PR+ stable disease with HI according to IWG 2006 criteria) of the administration of AG- 120 in each group (A and B) of patients. Cohort C: To determine the safety and tolerability of AG-120. We will use CTCAE version 5 for evaluation of non-hematological toxicities
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •Age ≥ 18 years
- •ECOG performance status 0-2 at the time of screening
- •Female subjects with reproductive potential must have a negative serum pregnancy test within 7 days prior to the start of therapy. Subjects with reproductive potential are defined as sexually mature women who have not undergone a hysterectomy, bilateral oophorectomy or tubal occlusion or who have not been naturally postmenopausal (i.e., who have not menstruated at all) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months). Females of reproductive potential as well as fertile men and their partners who are female of reproductive potential must agree to abstain from sexual intercourse or to use two highly effective forms of contraception from the time of giving informed consent, during the study and for 3 months (females and males) following the last dose of AG-
- •A highly effective form of contraception is defined as hormonal oral contraceptives, injectables, patches, intrauterine devices.
- •Male patients must : -Agree the need for the use of a condom if engaged in sexual activity with a woman of childbearing potential during the entire period of treatment, even if disruption of treatment and during 3 months after end of treatment. -Agree to learn about the procedures for preservation of sperm before starting treatment
- •Myelodysplastic syndrome according to WHO classification including non-proliferative AML up to 29% of BM blast: Belonging to one of the following categories : • higher risk (IPSS high or int 2 ) MDS without response to azacitidine (CR,PR, stable disease with HI) after at least 6 cycles , or relapsing after a response but without overt progression (defined by at least doubling of marrow blasts, compared to pre azacitidine bone marrow, or AML progression beyond 30% blasts) • Untreated higher risk MDS (IPSS int-2, high) without life threatening cytopenia including ANC <500/mm3 or any recent severe infections and /or platelets below 30,000/mm3 or any bleeding symptom • lower risk MDS with resistance or loss of response to a previous treatment with epoetin alpha/ beta (≥60000 U/w) or Darbopoetin (≥250 ug/w) given for at least 12 weeks and RBC transfusion requirement at least 2 U/8 weeks in the previous 16 weeks
- •Presence of IDH1 mutation in either blood or marrow prior to start of therapy
- •Normal renal function, defined by creatinine less than 1.5 times the upper limit of normal, creatinine clearance (Modification of diet in renal disease) creatinine clearance ≥ 50 mL/min
- •Normal liver function, defined by total bilirubin and transaminases less than 1.5 times the upper limit of normal
- •Adequate cardiac ejection fraction (>40%);
- •Patient is not known to be refractory to platelet transfusions;
- •Patient must understand and voluntarily sign consent form
- •Patient must be able to adhere to the visit schedule as outlined in the study and follow protocol requirements
排除标准
- •Severe infection or any other uncontrolled severe condition
- •Known HIV infection or active hepatitis B or C
- •Women who are or could become pregnant or who are currently breastfeeding
- •Any medical or psychiatric contraindication that would prevent the patient from understanding and signing the informed consent form
- •Patient eligible for allogeneic stem cell transplantation
- •Known allergies to AG-120 or any of its excipients
- •The study does not provide for the inclusion of persons referred to in Articles L. 1121-5 to L. 1121-9 and L. 1122-1-2 of the Public Health Code (e.g. minors, protected adults, etc.)
- •Subjects with a known medical history of progressive multifocal leukoencephalopathy (PML) should be excluded from the study
- •No affiliation to a health insurance system.
- •Significant cardiac disease - NYHA Class III or IV or having suffered a myocardial infarction in the last 6 months
- •Less than 14 days since prior treatment with growth factors (EPO, G-CSF)
- •Use of investigational agents within 30 days or any anticancer therapy within 2 weeks before the study entry with the exception of hydroxyurea. The patient must have recovered from all acute toxicity from any previous therapy.
- •Subject has a heart-rate corrected QT interval using Fridericia’s method (QTcF) ≥ 470 msec or any other factor that increases the risk of QT prolongation or arrhythmic events (e.g., heart failure, hypokalemia, family history of long QT interval syndrome). Subjects with prolonged QTcF interval in the setting of bundle branch block may participate in the study
- •Subject is taking known strong cytochrome P450 (CYP) 3A4 inducers or inhibitors or sensitive CYP3A4 substrate medications with a narrow therapeutic window, unless they can be transferred to other medications within ≥ 5 half-lives prior to dosing
- •Subject is taking P-glycoprotein (P-gp) transporter-sensitive substrate medications with a narrow therapeutic window, unless they can be transferred to other medications within ≥ 5 half-lives prior to administration of study treatment
- •Active cancer or cancer during the year prior to trial entry other than basal cell carcinoma, or carcinoma in situ of the cervix or breast
- •Patient already enrolled in another therapeutic trial of an investigational drug
结局指标
主要结局
Overall hematological response at 3 and 6 months (including CR, PR, stable disease with HI according to IWG 2006) for cohort A and B; SAFETY FOR COHORT C
Overall hematological response at 3 and 6 months (including CR, PR, stable disease with HI according to IWG 2006) for cohort A and B; SAFETY FOR COHORT C
次要结局
- Response duration and time response
- Time to IPSS and R-IPSS progression
- Rate and time to AML evolution
- Overall survival
- Cytogenetic and molecular response
- Prognostic factors of response, including IPSS-R, IPSS-karyotype and somatic mutations
- Evolution of IDH1 VAF on therapy
- Adverse events and toxicity as measured by NCI CTCAE 5
研究者
Marie SEBERT
Scientific
Groupe Francophone Des Myelodysplasies
研究点 (25)
Loading locations...
相似试验
招募中
2 期
A phase II trial of MK-3475 (pembrolizumab) in children and young adults with classical Hodgkin lymphoma2023-504821-38-00Merck Sharp & Dohme LLC195
招募中
3 期
Hyperthermic Intraperitoneal Chemotherapy in the treatment of Ovarian Cancer relapse2024-517390-24-00Unicancer, Unicancer383
招募中
2 期
Prospective study in patients with colon or rectum cancer with liver metastasis of the efficacy and toxicity of standard therapy (chemotherapy + targeted therapy) combined with immunotherapy and internal radiotherapy targeting the liver2024-517204-11-00Fondation Franc.Cancerologie Digestive52
已完成
1 期
[HIBOU] : A phase I, single-center, randomized, double-blind, single-dose escalation, placebo-controlled clinical study to evaluate the safety, tolerability and pharmacokinetics of IMP21052 administered intravenously in three groups of healthy male and female volunteers2023-509035-30-00Direction Centrale Du Service De Sante Des Armees40
招募中
2 期
A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS) (FUSION)2022-502552-31-00Biogen Idec Research Limited195